Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies

BACKGROUND: Immunotherapies represented by immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. A large part of the population has both cancer and psoriasis but is usually excluded from ICI clinical trials because of the dysregulated activation of the immune system. This is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yixuan, Zhou, Yang, Zhang, Xu, Tan, Kexin, Zheng, Jiabin, Li, Jia, Cui, Huijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334704/
https://www.ncbi.nlm.nih.gov/pubmed/35912183
http://dx.doi.org/10.3389/fonc.2022.934093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334704/
https://www.ncbi.nlm.nih.gov/pubmed/35912183
http://dx.doi.org/10.3389/fonc.2022.934093

Ejemplares similares